Schutte AE, Gona P, Delles C, et al. The African PRospective study on the Early Detection and Identification of Cardiovascular Disease and Hypertension (African-PREDICT): Design, recruitment and initial examination. Eur J Prevent Cardiol. 2019; 26: 458–470.
2.
SpenceJDRaynerBL. Hypertension in blacks: Individualized therapy based on renin/aldosterone phenotyping. Hypertension2018; 72: 263–269.
3.
SpenceJD. Hypertension in US-born vs. foreign-born African-Americans. J Hypertens2017; 35: 2369–2371.
4.
BakerEHDuggalADongYet al.Amiloride, a specific drug for hypertension in black people with T594M variant?Hypertension2002; 40: 13–17.
5.
JonesESSpenceJDMcIntyreADet al.High frequency of variants of candidate genes in black Africans with low renin-resistant hypertension. Am J Hypertens2017; 30: 478–483.
6.
JonesESOwenEPRaynerBL. The association of the R563Q genotype of the ENaC with phenotypic variation in southern Africa. Am J Hypertens2012; 25: 1286–1291.
7.
AkintundeANondiJGogoKet al.Physiological phenotyping for personalized therapy of uncontrolled hypertension in Africa. Am J Hypertens2017; 30: 923–930.
8.
StraussMSmithWKrugerRet al.Marinobufagenin and left ventricular mass in young adults: The African-PREDICT study. Eur J Prev Cardiol2018; 25: 1587–1595.
9.
LafferCLElijovichFEckertGJet al.Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: An exploratory pilot study in African Americans. J Am Soc Hypertens2014; 8: 475–480.
10.
AssieGLibeREspiardSet al.ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med2013; 369: 2105–2114.
